News >

Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm

Ellie Leick
Published: Monday, Oct 07, 2019

Mitchell R. Smith, MD, PhD, a professor of medicine and associate center director for Clinical Investigations in the Division of Hematology & Oncology and the George Washington Cancer Center

Mitchell R. Smith, MD, PhD

Chemoimmunotherapy has previously been a frontline standard of care for patients with chronic lymphocytic leukemia (CLL), but the emergence of targeted agents has led to a deeper understanding of how to optimally use these impactful drugs upfront and create practice-changing combinations, explained Mitchell R. Smith, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication